166410-34-0

Basic information

• Product Name: FMOC-NH(CH2)3NH2 HCL
• Synonyms: MONO-FMOC 1,3-DIAMINOPROPANE HYDROCHLORIDE;MONO-FMOC-1,3-PROPANEDIAMINE HYDROCHLORIDE;N1-(9-FLUORENYLMETHYLOXYCARBONYL)-1,3-DIAMINOPROPANE HYDROCHLORIDE;N-1-(9-FLUORENYLMETHOXYCARBONYL)-1,3 DIAMINOPROPANE HYDROCHLORIDE;N-1-FMOC-1,3-DIAMINOPROPANE HCL;N-(9-FLUORENYLMETHYLOXYCARBONYL)-1,3-DIAMINOPROPANE HYDROCHLORIDE;N-ALPHA-FMOC-1,3-DIAMINOPROPANE HYDROCHLORIDE;N-FMOC-1,3-DIAMINOPROPANE HYDROCHLORIDE
• CAS NO: 166410-34-0
• Molecular Formula: C₁₈H₂₀N₂O₂
• Molecular Weight: 332.82
• Mol File: 166410-34-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 497.3±28.0 °C(Predicted)
• Appearance: /
• Density: 1.178
• Storage Temp.: 2-8°C
• PKA: 12.10±0.46(Predicted)
• CAS DataBase Reference: FMOC-NH(CH2)3NH2 HCL(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-NH(CH2)3NH2 HCL(166410-34-0)
• EPA Substance Registry System: FMOC-NH(CH2)3NH2 HCL(166410-34-0)

Safety Data

• Hazardous Substances Data: 166410-34-0(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 102774-86-7 9-fluorenylmethyl N-succinimidyl carbonate 
• 109-76-2 Trimethylenediamine 

Relevant articles and documents

Interchangeable PEG-supported synthesis of peptide-oligonucleotide chimeras

A procedure has been developed for the preparation of peptide-PEG- oligonucleotide conjugates: the two sequences were synthesized at the extremities of the same commercial high-molecular-weight polyethylene glycol (PEG) starting both from the peptide as well as from the oligonucleotide component. The commercial PEG was modified at its terminal hydroxyl functions with two orthogonal protecting groups (DMT and Fmoc). The selective removal of those groups allowed the synthesis of the chimeras following two different, interchangeable strategies. Comparison of the final conjugates suggested that their production was equally effective. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.

Degradable hydrogel under physiological conditions

The present invention discloses a hydrogel that can be degraded under physiological conditions. The hydrogel includes at least one backbone moiety and an optional crosslinking moiety, and biodegradable linkers connecting backbone moieties and crosslinking moieties can be degraded by intramolecular cyclization.

BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS

Disclosed are promoieties of the following formula which can be used to form prodrugs of nitrogen-containing or hydroxyl-containing drug or a pharmaceutically active agent: (I) and pharmaceutical compositions comprising the prodrugs.